Table 3.
Complete response with immune checkpoint inhibitors in selected trials of advanced hepatocellular carcinoma
| Complete response according to | ||||
|---|---|---|---|---|
| Author, year (reference) | Compound (N of patients) | Radiological criteria used | Investigator assessment, N (%) | Central independent review, N (%) |
| Monotherapy | ||||
| Sangro, 2013 [69] | Tremelimumab (21) | RECIST | 0 | N/R |
| Crocenzi, 2016 [65] | Nivolumab (262) | RECIST 1.1 | 7 (2.7) | 4 (1.5) |
| Wainberg, 2017 [70] | Durvalumab (40) | RECIST 1.1 | 0 | N/R |
| Zhu, 2018 [66] | Pembrolizumab (104) | RECIST 1.1 | N/R | 1 (1) |
| Combination with checkpoint inhibitors | ||||
| Kelley, 2017 [71] | Durvalumab + tremelimumab (40) | RECIST 1.1 | 0 | N/R |
| Combination with ablation | ||||
| Duffy, 2017 [72] | Tremelimumab + subtotal ablation (32) | RECIST 1.1 | 0 | N/R |
| Combination with targeted therapies | ||||
| Ikeda, 2018 [67] | Lenvatinib + pembrolizumab (26) | mRECIST | 1 (3.8) | N/R |
| Stein, 2018 [68] | Atezolizumab + bevacizumab (23) | RECIST 1.1 | 0 | 1 (4.3) |
mRECIST modified Response Evaluation Criteria in Solid Tumors; N/R not reported; RECIST Response Evaluation Criteria in Solid Tumors; RECIST 1.1 Response Evaluation Criteria in Solid Tumors version 1.1